Published in Nat Rev Nephrol on July 06, 2010
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol (2013) 1.76
Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol (2011) 1.66
Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol (2012) 1.58
The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice. Kidney Int (2012) 1.52
A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol (2012) 1.52
C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest (2013) 1.52
Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol (2012) 1.43
Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J Am Soc Nephrol (2012) 1.40
Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol (2012) 1.34
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Recent insights into C3 glomerulopathy. Nephrol Dial Transplant (2013) 1.21
C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol (2013) 1.19
Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. Am J Transplant (2010) 1.16
Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens (2013) 1.07
Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol (2013) 1.07
Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol (2014) 1.03
Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis (2012) 1.03
Dense deposit disease and C3 glomerulopathy. Semin Nephrol (2013) 0.98
Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol (2014) 0.97
Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol (2016) 0.97
Properdin in complement activation and tissue injury. Mol Immunol (2013) 0.95
C3 nephritic factor associated with C3 glomerulopathy in children. Pediatr Nephrol (2013) 0.91
The renal biopsy in the genomic era. Pediatr Nephrol (2012) 0.89
Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol (2014) 0.88
Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol (2013) 0.88
Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J (2015) 0.87
Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis Model Mech (2011) 0.87
Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol (2014) 0.86
Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int (2015) 0.84
Eculizumab in Pediatric Dense Deposit Disease. Clin J Am Soc Nephrol (2015) 0.84
C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo. Clin Exp Immunol (2014) 0.82
Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? Pediatr Nephrol (2011) 0.81
Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come. Clin Dev Immunol (2012) 0.81
Pathogenesis of glomerular haematuria. World J Nephrol (2015) 0.81
Successful treatment of infectious endocarditis associated glomerulonephritis mimicking c3 glomerulonephritis in a case with no previous cardiac disease. Case Rep Nephrol (2014) 0.80
C4d Staining in the Diagnosis of C3 Glomerulopathy. J Am Soc Nephrol (2015) 0.80
C3 mesangial proliferative glomerulonephritis initially presenting with atypical hemolytic uremic syndrome: a case report. J Med Case Rep (2016) 0.79
C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Pediatr Nephrol (2016) 0.78
Complement in ANCA-associated vasculitis. Semin Nephrol (2013) 0.78
CD11b is protective in complement-mediated immune complex glomerulonephritis. Kidney Int (2015) 0.78
Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy. Clin Kidney J (2013) 0.78
Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report. BMC Res Notes (2014) 0.78
Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging. Adv Chronic Kidney Dis (2013) 0.78
Human C3 glomerulopathy provides unique insights into complement factor H-related protein function. J Clin Invest (2013) 0.77
Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol (2013) 0.76
Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice. J Immunol (2012) 0.76
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol (2016) 0.76
The absence of immunoglobulin D B cell receptor-mediated signals promotes the production of autoantibodies and exacerbates glomerulonephritis in murine lupus. Clin Exp Immunol (2011) 0.76
A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol (2015) 0.76
Complement cascade and kidney transplantation: The rediscovery of an ancient enemy. World J Transplant (2014) 0.76
Chapter 8: Idiopathic membranoproliferative glomerulonephritis. Kidney Int Suppl (2011) (2012) 0.75
C3 glomerulopathy. F1000Res (2017) 0.75
A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency. CEN Case Rep (2013) 0.75
Protracted Clinical Course of Postinfectious Glomerulonephritis in a Previously Healthy Child. Case Rep Nephrol Dial (2016) 0.75
New classification of membranoproliferative glomerulonephritis: a good start but a long way to go. Kidney Res Clin Pract (2014) 0.75
C3 glomerulonephritis in multiple myeloma: A case report and literature review. Medicine (Baltimore) (2016) 0.75
Reanalysis of membranoproliferative glomerulonephritis patients according to the new classification: a multicenter study. Kidney Res Clin Pract (2014) 0.75
Atypical Plasmacytic Proliferation in a Case of C3 Glomerulopathy: Pathophysiology Demystified. J Investig Med High Impact Case Rep (2017) 0.75
Kidney transplant outcomes in familial C3 glomerulopathy. Clin Kidney J (2016) 0.75
Membranoproliferative glomerulonephritis and x-linked agammaglobulinemia: an uncommon association. Case Rep Pediatr (2014) 0.75
Post-infectious glomerulonephritis with crescents in adults: a retrospective study. Clin Kidney J (2016) 0.75
Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis (2014) 0.75
C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. Kidney Int (2017) 0.75
Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience. Diagn Pathol (2015) 0.75
Incidence and profile of C3 Glomerulopathy: A single center study. Indian J Nephrol (2015) 0.75
Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol (2016) 0.75
C3 glomerulopathy and current dilemmas. Clin Exp Nephrol (2016) 0.75
Current status of pediatric renal transplant pathology. Pediatr Nephrol (2016) 0.75
Positive C1q staining associated with poor renal outcome in membranoproliferative glomerulonephritis. Clin Exp Nephrol (2012) 0.75
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol (2008) 2.08
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol (2008) 1.89
Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol (2007) 1.88
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Membranoproliferative glomerulonephritis. Pediatr Nephrol (2009) 1.80
Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med (1983) 1.70
Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int (1975) 1.59
Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med (2008) 1.55
The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet (2009) 1.52
The amplification loop of the complement pathways. Adv Immunol (2009) 1.46
Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci U S A (2009) 1.36
Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost (2009) 1.33
Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol (2002) 1.31
Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 1.31
Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis. J Clin Invest (1971) 1.31
Where next with atypical hemolytic uremic syndrome? Mol Immunol (2007) 1.23
Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis (2001) 1.15
Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am J Kidney Dis (1989) 1.08
Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN) Clin Immunol Immunopathol (1978) 1.05
Familial membranoproliferative glomerulonephritis type III. Am J Kidney Dis (2002) 0.97
Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature (2006) 9.30
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet (2007) 5.93
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet (2002) 4.22
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 3.99
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol (2010) 3.48
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis (2013) 3.39
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med (2004) 3.32
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant (2011) 2.51
Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell (2013) 2.49
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int (2011) 2.20
Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. Nephrol Dial Transplant (2007) 2.17
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant (2011) 2.03
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells (2006) 1.90
High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol (2007) 1.90
The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2010) 1.88
C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol (2002) 1.88
Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood (2005) 1.86
ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant (2005) 1.84
Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol (2006) 1.82
Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int (2002) 1.78
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant (2008) 1.76
Complement in human diseases: Lessons from complement deficiencies. Mol Immunol (2009) 1.73
Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol (2004) 1.68
Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol (2008) 1.68
Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol (2011) 1.66
Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A (2013) 1.63
Interferon-beta reduces proteinuria in experimental glomerulonephritis. J Am Soc Nephrol (2007) 1.63
Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A (2007) 1.62
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol (2003) 1.54
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol (2012) 1.52
C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest (2013) 1.52
A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol (2011) 1.51
Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol (2011) 1.50
ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation (2008) 1.48
Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int (2003) 1.48
Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant (2003) 1.48
Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. J Hum Genet (2012) 1.46
Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J Am Soc Nephrol (2006) 1.46
Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int (2002) 1.44
Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis (2002) 1.44
Proliferation of bone marrow-derived cells contributes to regeneration after folic acid-induced acute tubular injury. J Am Soc Nephrol (2005) 1.41
Non-hepatitis virus associated mixed essential cryoglobulinemia. Kidney Int (2009) 1.40
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Genetic dissection of spontaneous autoimmunity driven by 129-derived chromosome 1 Loci when expressed on C57BL/6 mice. J Immunol (2007) 1.34
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility. Nat Genet (2008) 1.31
Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood (2010) 1.31
Dense deposit disease. Mol Immunol (2011) 1.31
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood (2004) 1.30
Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int (2010) 1.25
The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med (2013) 1.23
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) (2004) 1.21
Recent insights into C3 glomerulopathy. Nephrol Dial Transplant (2013) 1.21
The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis (2003) 1.21
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol (2009) 1.21
Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.20
C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol (2013) 1.19
The follicular dendritic cell restricted epitope, FDC-M2, is complement C4; localization of immune complexes in mouse tissues. Eur J Immunol (2002) 1.19
Crescentic glomerulonephritis: new aspects of pathogenesis. Semin Nephrol (2011) 1.18
C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood (2013) 1.18
High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant (2006) 1.17
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant (2009) 1.15
Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens (2011) 1.14
Renal involvement in Castleman disease. Nephrol Dial Transplant (2010) 1.13
Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice. J Immunol (2006) 1.12